BACKGROUND Health-related quality of life (HRQoL) is impaired in untreated patients with gastroesophageal reflux disease (GERD). In the absence of an objective marker such as erosions, assessment of treatment efficacy can be based on symptoms and HRQoL. OBJECTIVE To evaluate changes in HRQoL during treatment with pantoprazole or nizatidine in patients with GERD. METHODS This was a prospecti...

BACKGROUND Pantoprazole is a selective inhibitor of the gastric H+/K+-ATPase with a low potential to interact with the cytochrome P450 enzyme system. Since pantoprazole is metabolized in the liver to metabolites which are mainly cleared by the renal route, it was the aim of this study to investigate its pharmacokinetics in patients with end-stage renal failure undergoing regular haemodialysis. ...

BACKGROUND Proton pump is an integral membrane protein that is ubiquitous ATP binding cassette (ABC) involved in many transport processes in all living organisms, among which a specialized form of pump, so called p-type proton pump, exists in the parietal cells of stomach. Though proton pump inhibitors (PPIs) are frequently prescribed to prevent nonsteroidal anti-inflammatory drugs (NSAIDs)-ind...

Background: The aim was determining bioequivalence between pantoprazole buffered powder for oral suspension and enteric coated tablets under fasting conditions in healthy volunteers.Methods: In randomized cross-over study, participants were administered a single dose of as 40 mg (sodium bicarbonate buffer) or one tablet mg, with 240±2 ml water per the randomization schedule each study period. B...